IMVT · Immunovant Inc
United States · RS rating 33 · As of 2026-10-14
| Price | 27.90 USD |
|---|---|
| 1-day change | -2.8% |
| RS rating (overall / 1M / 3M / 12M) | 33 / 9 / 13 / 91 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 31 / 36 / 42 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +16.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +37.9% |
| Market cap (USD) | $5.9B |